Is RMD a good stock to buy?
ResMed Inc. · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 21
- P/E vs sector-32.1%
- FCF yield+8.5%
- Trendbullish
- MAs3 of 4
- Sector▲ +15.9%
- Earnings in76d
- P/E21.9x
- RSI53
- Support-4.7%
- Resistance+0.6%
- Off 52w high-13.7%
- Volume0.6x
- Bollingerlower half
- News0.00
- P/E vs own+3.6%
- PT$251.42 +5.0%
- 52w range$180–$278
- ATR+3.0%
- Off ATH-20.5%
- Insiders-$3.74M
- MACD-0.82
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is ResMed a good stock to buy?
ResMed is strong on 5 of the 5 questions about the business. The price is low: 21.9 times its earnings, below its 3-year median of 27.1 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage hard to copy
- Economics very profitable
- Execution delivers
- Fragility sturdy
- Price below its usual
RMD sales growth revenue growth
+10%a year, for the last 3 yearsResMed's sales grew 10% a year for 3 years, to $5.65B in fiscal 2026.
RMD analysts' forecast revenue estimates
+3%the sales they expect next fiscal year, on the lastAnalysts expect ResMed's sales to grow 3% to $5.83B in fiscal 2027 (22 analysts).
RMD competitors
pretickt analysis+9%its sales in 12 months, on a year before
ResMed's sales grew 9% in the 12 months to Sep 30, 2026, faster than Baxter (+5%), Solventum (-3%) and Becton Dickinson (-7%), slower than West Pharmaceutical Services (+13%).
RMD sales by business revenue by segment
88%of its sales from Sleep And RespiratorySleep And Respiratory brought ResMed 88% of its sales in fiscal 2024; Software As Service 12%.
RMD return on capital ROIC
pretickt analysis34%earned before tax on the money invested in itResMed earned 34% before tax on the capital invested in it in the 12 months to Sep 30, 2026; West Pharmaceutical Services 28%, Solventum 21%, Becton Dickinson 4% and Baxter -2%.
RMD margin on each sale gross margin
61%left after making the productResMed kept 61% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 42%.
RMD margin after costs profit margin
33%of sales left after running the businessResMed's operating margin was 33% in the 12 months to Sep 30, 2026, against 27% in fiscal 2023.
RMD earnings vs estimates
7 of 8quarters above the analysts' estimateResMed beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 29, 2026.
RMD insider selling
-$20.16Msold, net, by its executives in 12 monthsResMed's executives and directors sold a net $20.16M of shares in the 12 months to Nov 13, 2026; none bought.
RMD number of employees
+7%more people in a yearResMed had 11,370 employees at the end of fiscal 2026, 7% more than a year before.
RMD CEO pay
$16.2Mfor fiscal 2026, 80% of it in stock and optionsResMed paid its CEO $16.2M for fiscal 2026, 80% of it in stock and options.
RMD financial health Altman Z-score
12.0Altman Z-score, safe above 3ResMed's Altman Z-score is 12.0 (Nov 13, 2026), above 3, where the safe zone starts.
RMD quality checks Piotroski score
8 of 9checks passedResMed passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio.
RMD biggest customers
under 10%of sales from any one customerNo customer made 10% of ResMed's sales in fiscal 2026.
RMD in past recessions
pretickt analysis+10%its sales in the worst oneResMed's sales grew through each of the last 2 US recessions (2008–09 and 2020).
RMD price vs profit P/E ratio
21.9×a year's earningsResMed's P/E ratio is 21.9 (Nov 13, 2026), below its 3-year median of 27.1.
RMD price vs competitors
pretickt analysis21.9×a year's earnings, against its competitorsInvestors pay 21.9 times ResMed's earnings (Nov 13, 2026), less than for Solventum (99.0), Becton Dickinson (52.7) or West Pharmaceutical Services (46.7).
RMD analysts' target price target
+5%to their average targetAnalysts' average price target for ResMed is $251, 5% above the Nov 13, 2026 close of $239.53.
RMD analyst ratings, 90 days
pretickt analysisRBC Capitalupgrade Canaccord Genuitydowngrade
In the 90 days to Nov 13, 2026, RBC Capital upgraded ResMed; Canaccord Genuity downgraded it.
What is ResMed's P/E ratio?
ResMed's P/E ratio is 21.9 (Nov 13, 2026), below its 3-year median of 27.1. Investors pay 21.9 times ResMed's earnings (Nov 13, 2026), less than for Solventum (99.0), Becton Dickinson (52.7) or West Pharmaceutical Services (46.7).
Who are ResMed's biggest competitors?
pretickt compares ResMed with West Pharmaceutical Services, Becton Dickinson, Solventum and Baxter. ResMed's sales grew 9% in the 12 months to Sep 30, 2026, faster than Baxter (+5%), Solventum (-3%) and Becton Dickinson (-7%), slower than West Pharmaceutical Services (+13%).
Is ResMed profitable?
ResMed's operating margin was 33% in the 12 months to Sep 30, 2026, against 27% in fiscal 2023.
Are insiders selling ResMed stock?
ResMed's executives and directors sold a net $20.16M of shares in the 12 months to Nov 13, 2026; none bought.
How does ResMed make money?
Sleep And Respiratory brought ResMed 88% of its sales in fiscal 2024; Software As Service 12%.
How many employees does ResMed have?
ResMed had 11,370 employees at the end of fiscal 2026, 7% more than a year before.
Who are ResMed's biggest customers?
No customer made 10% of ResMed's sales in fiscal 2026.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.